A Nantes company promises a “much more effective vaccine than those large laboratories are working on”

12:07 12.11.2020(updated 12:18 12.11.2020) Short URL

https://cdnfr1.img.sputniknews.com/img/102583/03/1025830386_0:32:3600:2057_1200x675_80_0_0_5ffe0c32c99947760f46b002b175e877.jpg

https://fr.sputniknews.com/france/202011121044757132-une-societe-nantaise-promet-un-vaccin-bien-plus-efficace-que-ceux-sur-lesquels-travaillent-les/

A single injection for several years, easy storage and a low price, a promising Covid-19 vaccine has been announced for the end of 2021 at the earliest by a Nantes biotech company. According to these researchers, this remedy may be more effective in the long run than those large laboratories are working on.

In addition to large pharmaceutical laboratories, Nantes-based OSE Immunotherapeutics is also working on a vaccine against Covid-19, reports France Bleu.

According to regional media, these researchers promise “a much more effective vaccine than large laboratories are currently working on,” because a single injection can protect patients for many years despite the virus mutation. To accomplish this, the lab hopes that instead of reacting the antibodies, the vaccine will cause the white blood cells to react, which works on all known forms of Covid-19.

Moreover, according to the promises of the company from Nantes, the vaccine could be stored in a simple refrigerator and cost no more than 10 euros.

France Bleu indicates that the first human tests are expected to begin early next year, while its commercialization is not expected until the end of 2021 at the earliest.

The vaccine at the center of Sanofi research

Laboratories around the world are mobilizing in the fight against the coronavirus. On 3 September, the French pharmaceutical giant Sanofi, associated with the English GSK, also announced the launch of its first phase I-II clinical trial. Its vaccine candidate is based on recombinant protein technology already used by Sanofi, plus an adjuvant developed by GSK.